Literature DB >> 18366995

Nonalcoholic fatty liver disease: diagnosis and relation to metabolic syndrome and approach to treatment.

Steven D Lidofsky1.   

Abstract

Nonalcoholic fatty liver disease is an increasingly prevalent disorder that spans a range of conditions from hepatic steatosis to cirrhosis. It is commonly associated with obesity and diabetes, two components of the metabolic syndrome. Although hepatic steatosis may be reversible, disease progression appears to be triggered by overproduction of reactive oxygen species and mitochondrial injury in hepatocytes. Evolving treatments are focused on reversing insulin resistance, which underlies many of the metabolic derangements in this disease.

Entities:  

Mesh:

Year:  2008        PMID: 18366995     DOI: 10.1007/s11892-008-0006-1

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  60 in total

Review 1.  Is weight reduction an effective therapy for nonalcoholic fatty liver? A systematic review.

Authors:  Rex T Wang; Ronald L Koretz; Hal F Yee
Journal:  Am J Med       Date:  2003-11       Impact factor: 4.965

2.  Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial.

Authors:  Keith D Lindor; Kris V Kowdley; E Jenny Heathcote; M Edwyn Harrison; Roberta Jorgensen; Paul Angulo; James F Lymp; Lawrence Burgart; Patrick Colin
Journal:  Hepatology       Date:  2004-03       Impact factor: 17.425

3.  Prevalence of and risk factors for hepatic steatosis in Northern Italy.

Authors:  S Bellentani; G Saccoccio; F Masutti; L S Crocè; G Brandi; F Sasso; G Cristanini; C Tiribelli
Journal:  Ann Intern Med       Date:  2000-01-18       Impact factor: 25.391

4.  Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

Authors:  P Angulo; J C Keach; K P Batts; K D Lindor
Journal:  Hepatology       Date:  1999-12       Impact factor: 17.425

5.  Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease.

Authors:  I R Willner; B Waters; S R Patil; A Reuben; J Morelli; C A Riely
Journal:  Am J Gastroenterol       Date:  2001-10       Impact factor: 10.864

6.  Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease.

Authors:  Raphael B Merriman; Linda D Ferrell; Marco G Patti; Shiobhan R Weston; Mark S Pabst; Bradley E Aouizerat; Nathan M Bass
Journal:  Hepatology       Date:  2006-10       Impact factor: 17.425

7.  Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis.

Authors:  Shiro Yokohama; Masashi Yoneda; Masakazu Haneda; Satoshi Okamoto; Mituyoshi Okada; Kazunobu Aso; Takenao Hasegawa; Yoshihiko Tokusashi; Naoyuki Miyokawa; Kimihide Nakamura
Journal:  Hepatology       Date:  2004-11       Impact factor: 17.425

8.  Non-alcoholic steatohepatitis in type 2 diabetes mellitus.

Authors:  Parijat Gupte; Deepak Amarapurkar; Subhash Agal; Rajiv Baijal; Pramod Kulshrestha; Snehansu Pramanik; Nikhil Patel; Aruna Madan; Anjali Amarapurkar
Journal:  J Gastroenterol Hepatol       Date:  2004-08       Impact factor: 4.029

9.  Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values.

Authors:  Pouneh Mofrad; Melissa J Contos; Mahmadul Haque; Carol Sargeant; Robert A Fisher; Velimir A Luketic; Richard K Sterling; Mitchell L Shiffman; Richard T Stravitz; Arun J Sanyal
Journal:  Hepatology       Date:  2003-06       Impact factor: 17.425

10.  Beyond insulin resistance in NASH: TNF-alpha or adiponectin?

Authors:  Jason M Hui; Alex Hodge; Geoffrey C Farrell; James G Kench; Adamandia Kriketos; Jacob George
Journal:  Hepatology       Date:  2004-07       Impact factor: 17.425

View more
  10 in total

1.  Centrizonal arteries and microvessels in nonalcoholic steatohepatitis.

Authors:  Ryan M Gill; Patricia Belt; Laura Wilson; Nathan M Bass; Linda D Ferrell
Journal:  Am J Surg Pathol       Date:  2011-09       Impact factor: 6.394

2.  Positive correlations of liver enzymes with metabolic syndrome including insulin resistance in newly diagnosed type 2 diabetes mellitus.

Authors:  Yifei Zhang; Xi Lu; Jie Hong; Menglei Chao; Weiqiong Gu; Weiqing Wang; Guang Ning
Journal:  Endocrine       Date:  2010-10-23       Impact factor: 3.633

3.  Non-alcoholic fatty liver disease: An early mediator predicting metabolic syndrome in obese children?

Authors:  Jun-Fen Fu; Hong-Bo Shi; Li-Rui Liu; Ping Jiang; Li Liang; Chun-Lin Wang; Xi-Yong Liu
Journal:  World J Gastroenterol       Date:  2011-02-14       Impact factor: 5.742

4.  PFP alleviates nonalcoholic steatohepatitis fatty liver in both Apo E-/- mice and Changliver cell[S].

Authors:  Dong Yan; Yuan-Yuan Wei; Xiu-Mei Li; Xiu-Chao Sun; Zhong Wang; Haji Akber Aisa
Journal:  Am J Transl Res       Date:  2017-06-15       Impact factor: 4.060

5.  Non alcoholic fatty liver disease and metabolic syndrome.

Authors:  P Paschos; K Paletas
Journal:  Hippokratia       Date:  2009-01       Impact factor: 0.471

6.  Suboptimal maternal nutrition, during early fetal liver development, promotes lipid accumulation in the liver of obese offspring.

Authors:  M A Hyatt; D S Gardner; S Sebert; V Wilson; N Davidson; Y Nigmatullina; L L Y Chan; H Budge; M E Symonds
Journal:  Reproduction       Date:  2010-11-02       Impact factor: 3.906

7.  Alanine aminotransferase and risk of the metabolic syndrome: a linear dose-response relationship.

Authors:  Setor K Kunutsor; Dorothy Seddoh
Journal:  PLoS One       Date:  2014-04-29       Impact factor: 3.240

8.  Long-term change in incidence and risk factors of cirrhosis and hepatocellular carcinoma in Crete, Greece: a 25-year study.

Authors:  Spyridon A Karageorgos; Soultana Stratakou; Mairi Koulentaki; Argyro Voumvouraki; Aikaterini Mantaka; Dimitrios Samonakis; George Notas; Elias A Kouroumalis
Journal:  Ann Gastroenterol       Date:  2017-03-23

9.  Circulating total bilirubin and risk of non-alcoholic fatty liver disease in the PREVEND study: observational findings and a Mendelian randomization study.

Authors:  Setor K Kunutsor; Monika Frysz; Niek Verweij; Lyanne M Kieneker; Stephan J L Bakker; Robin P F Dullaart
Journal:  Eur J Epidemiol       Date:  2019-11-26       Impact factor: 8.082

10.  Association of Alanine Aminotransferase Levels (ALT) with the Hepatic Insulin Resistance Index (HIRI): a cross-sectional study.

Authors:  Miguel Angel Gómez-Sámano; Daniel Cuevas-Ramos; Roopa Mehta; Hasan Brau-Figueroa; Clara Elena Meza-Arana; Alfonso Gulias-Herrero
Journal:  BMC Endocr Disord       Date:  2012-09-04       Impact factor: 2.763

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.